6.
Massimiani M, Vecchione L, Piccirilli D, Spitalieri P, Amati F, Salvi S
. Epidermal growth factor-like domain 7 promotes migration and invasion of human trophoblast cells through activation of MAPK, PI3K and NOTCH signaling pathways. Mol Hum Reprod. 2015; 21(5):435-51.
PMC: 4492406.
DOI: 10.1093/molehr/gav006.
View
7.
Shah S, Brock E, Ji K, Mattingly R
. Ras and Rap1: A tale of two GTPases. Semin Cancer Biol. 2018; 54:29-39.
PMC: 6170734.
DOI: 10.1016/j.semcancer.2018.03.005.
View
8.
Stremitzer S, Zhang W, Yang D, Ning Y, Sunakawa Y, Matsusaka S
. Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. Mol Cancer Ther. 2016; 15(11):2814-2821.
PMC: 8547597.
DOI: 10.1158/1535-7163.MCT-16-0275.
View
9.
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S
. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015; 16(13):1306-15.
DOI: 10.1016/S1470-2045(15)00122-9.
View
10.
Xu H, Chen L, Liu X, Zhan Y, Zhang H, Li Q
. Targeting EGFL7 expression through RNA interference suppresses renal cell carcinoma growth by inhibiting angiogenesis. Asian Pac J Cancer Prev. 2014; 15(7):3045-50.
DOI: 10.7314/apjcp.2014.15.7.3045.
View
11.
Samur M
. RTCGAToolbox: a new tool for exporting TCGA Firehose data. PLoS One. 2014; 9(9):e106397.
PMC: 4152273.
DOI: 10.1371/journal.pone.0106397.
View
12.
Deng Q, Xie L, Li H
. Overexpressed MALAT1 promotes invasion and metastasis of gastric cancer cells via increasing EGFL7 expression. Life Sci. 2016; 157:38-44.
DOI: 10.1016/j.lfs.2016.05.041.
View
13.
Hansen T, Nielsen B, Sorensen F, Johnsson A, Jakobsen A
. Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer. Mol Cancer Ther. 2014; 13(9):2238-45.
DOI: 10.1158/1535-7163.MCT-14-0131.
View
14.
Colaprico A, C Silva T, Olsen C, Garofano L, Cava C, Garolini D
. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2015; 44(8):e71.
PMC: 4856967.
DOI: 10.1093/nar/gkv1507.
View
15.
Bos J, de Rooij J, Reedquist K
. Rap1 signalling: adhering to new models. Nat Rev Mol Cell Biol. 2001; 2(5):369-77.
DOI: 10.1038/35073073.
View
16.
Luo B, Xiong F, Wang J, Li J, Zhong M, Liu Q
. Epidermal growth factor-like domain-containing protein 7 (EGFL7) enhances EGF receptor-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells. PLoS One. 2014; 9(6):e99922.
PMC: 4063792.
DOI: 10.1371/journal.pone.0099922.
View
17.
Johnson L, Huseni M, Smyczek T, Lima A, Yeung S, Cheng J
. Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. J Clin Invest. 2013; 123(9):3997-4009.
PMC: 3754254.
DOI: 10.1172/JCI67892.
View
18.
Yu G, Wang L, Han Y, He Q
. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7.
PMC: 3339379.
DOI: 10.1089/omi.2011.0118.
View
19.
Wu F, Yang L, Li Y, Ou D, Chen D, Fan C
. Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. Hepatology. 2009; 50(6):1839-50.
DOI: 10.1002/hep.23197.
View
20.
von Pawel J, Spigel D, Ervin T, Losonczy G, Barlesi F, Juhasz E
. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer. Oncologist. 2018; 23(6):654-e58.
PMC: 6067939.
DOI: 10.1634/theoncologist.2017-0690.
View